Figure 2: (a) Overall survival (OS) and progression-free survival (PFS) for the cohort of 256 diffuse large B-cell lymphoma (DLBCL) patientís post-autologous peripheral hematopoietic stem cell transplantation (APHSCT). The 5-year OS and PFS rates were 50% and 45%, respectively. (b) The OS based on patients treated with rituximab versus no rituximab prior to transplant: the 3-year OS rates for rituximab versus no rituximab of 66% versus 42%, p < 0.0001, respectively. (c) The progression-freesurvival (PFS) based on patients treated with rituximab versus no rituximab prior to transplant: the 3-year PFS rates for rituximab versus no rituximab of 57% versus 38%, p < 0.0001, respectively. (d) Cumulative mortality incidence for relapse mortality (RM) and non-relapse mortality (NRM). The ten-year estimated incidence of RM and NRM was 30% and 15%, respectively.